Anika Therapeutics is closely monitoring the evolving COVID-19 (coronavirus) situation and the guidance from global, national and local health authorities. We have taken several steps to safeguard the health of our employees worldwide, support the needs of our partners, and ensure patients have the treatments they need. We are also actively working with industry partners to donate supplies to meet the urgent needs of healthcare providers.
In accordance with guidance issued by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and local health authorities, we have directed our employees to work remotely from home whenever possible. We have cancelled or postponed all face-to-face meetings and events and halted business travel until further notice to help reduce the spread of the virus. In addition, we have implemented additional protective measures at all of our production facilities and provided guidance to all Anika employees regarding proper health and hygiene practices in accordance with recommendations from global, national, and local health authorities.
We are closely monitoring our manufacturing and supply chain resources and we are taking measures to ensure product availability globally. At this time, we do not anticipate disruption to the supply of our products for patients due to COVID-19. We have also taken measures to minimize any disruption to ongoing clinical trials and are working with trial sites and other partners to ensure our trials continue to be conducted in a safe manner.
Our hearts go out to everyone impacted by COVID-19 during this uncertain time. Patients who have questions or concerns regarding their treatments with our products should contact their health care provider. For questions about our products, please contact firstname.lastname@example.org. Information and guidance on COVID-19 is available from the WHO and CDC.
Anika has acquired Arthrosurface, a leading, privately-held provider of joint surface and preservation solutions for active patients, and Parcus Medical, a leading, privately-held sports medicine company.
A clinical trial involves research using human volunteers and is intended to collect data that will add to medical knowledge. Below are our product(s) that currently have an ongoing clinical trial. Click the product to learn more.
Inspired by Nature.
Perfected by Science.
Anika is a leading manufacturer of products designed to help protect, heal and regenerate tissue.
Our proprietary technology is based on hyaluronic acid (HA), a naturally occurring biocompatible molecule found throughout the body, and a vital component of healthy joint and tissue function.
Safe and natural solutions help restore active function
Anika’s orthobiologics products are designed to help patients return to their active lives more quickly and naturally.
Our comprehensive portfolio of viscosupplementation products addresses the joint pain associated with osteoarthritis.
Naturally powerful solutions to manage wounds
Anika offers a range of therapeutic solutions designed for wound management. Our proprietary technology utilizes naturally-sourced hyaluronic acid (HA), a natural component of the body vital for maintaining the elasticity and function of healthy tissue.
Safe and natural protection against adhesions
Hyaluronic acid (HA) is a naturally occurring polymer found throughout the body. HA is vital for maintaining the function of healthy tissue, and can be used for a variety of applications. Anika’s innovative, all-natural HA-based barriers work to prevent or reduce post-surgical adhesions.
OTHER HA SOLUTIONS
Naturally Inspired Therapeutics
Anika’s other product solutions address a broad range of therapeutic areas, including ophthalmic, dental and veterinary.
Tactoset™ is a new injectable bone substitute which contains Anika’s proprietary hyaluronic acid formulation.